BR112013015001B1 - Peptídeo antitumor isolado ou sintético, composição farmacêutica, e, usos de um peptídeo - Google Patents

Peptídeo antitumor isolado ou sintético, composição farmacêutica, e, usos de um peptídeo Download PDF

Info

Publication number
BR112013015001B1
BR112013015001B1 BR112013015001-7A BR112013015001A BR112013015001B1 BR 112013015001 B1 BR112013015001 B1 BR 112013015001B1 BR 112013015001 A BR112013015001 A BR 112013015001A BR 112013015001 B1 BR112013015001 B1 BR 112013015001B1
Authority
BR
Brazil
Prior art keywords
peptide
cancer
cells
tumor
peptides
Prior art date
Application number
BR112013015001-7A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013015001A8 (pt
BR112013015001A2 (pt
Inventor
Luiz Rodolpho Raja Gabaglia Travassos
Original Assignee
Recepta Biopharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recepta Biopharma S.A. filed Critical Recepta Biopharma S.A.
Publication of BR112013015001A2 publication Critical patent/BR112013015001A2/pt
Publication of BR112013015001A8 publication Critical patent/BR112013015001A8/pt
Publication of BR112013015001B1 publication Critical patent/BR112013015001B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/10—Bryophyta (mosses)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112013015001-7A 2010-12-14 2011-12-14 Peptídeo antitumor isolado ou sintético, composição farmacêutica, e, usos de um peptídeo BR112013015001B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42285610P 2010-12-14 2010-12-14
US61/422,856 2010-12-14
PCT/IB2011/003053 WO2012080822A2 (en) 2010-12-14 2011-12-14 Antitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to napi2b transporter

Publications (3)

Publication Number Publication Date
BR112013015001A2 BR112013015001A2 (pt) 2017-12-19
BR112013015001A8 BR112013015001A8 (pt) 2018-04-17
BR112013015001B1 true BR112013015001B1 (pt) 2021-10-13

Family

ID=46245158

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013015001-7A BR112013015001B1 (pt) 2010-12-14 2011-12-14 Peptídeo antitumor isolado ou sintético, composição farmacêutica, e, usos de um peptídeo

Country Status (8)

Country Link
US (2) US9193797B2 (https=)
EP (1) EP2654769B1 (https=)
JP (1) JP6087289B2 (https=)
BR (1) BR112013015001B1 (https=)
CO (1) CO6721014A2 (https=)
ES (1) ES2804476T3 (https=)
PT (1) PT2654769T (https=)
WO (1) WO2012080822A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016013258A2 (pt) * 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
CN105491524B (zh) * 2015-12-11 2019-04-26 小米科技有限责任公司 一种确定目标便携设备位置的方法和装置
JP7194180B2 (ja) * 2017-07-01 2022-12-21 レセプタ バイオファーマ エッシ ア ペプチドを使用する方法及び樹状細胞を調節する方法
EP3685166A2 (en) * 2017-09-20 2020-07-29 Mersana Therapeutics, Inc. Compositions and methods for predicting response to napi2b-targeted therapy
WO2022032228A1 (en) 2020-08-07 2022-02-10 The Broad Institute, Inc. Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
KR102822203B1 (ko) 2020-12-29 2025-06-18 삼성전자주식회사 전력 공급 장치를 이용하여 오디오 출력 장치를 찾는 방법 및 그 전력 공급 장치
CN116514926B (zh) * 2023-06-25 2023-08-29 烟台药物研究所 一种抗肿瘤阳离子两亲肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
AU684348B2 (en) * 1994-06-07 1997-12-11 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide
US6689753B1 (en) 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
WO2005040219A1 (en) * 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
WO2009097128A1 (en) 2008-01-29 2009-08-06 Ludwig Institute For Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
WO2012080822A9 (en) 2016-08-11
JP6087289B2 (ja) 2017-03-01
BR112013015001A8 (pt) 2018-04-17
CO6721014A2 (es) 2013-07-31
EP2654769A4 (en) 2017-10-25
EP2654769B1 (en) 2020-04-15
US20130315902A1 (en) 2013-11-28
ES2804476T3 (es) 2021-02-08
US9193797B2 (en) 2015-11-24
US20160108132A1 (en) 2016-04-21
US9896512B2 (en) 2018-02-20
PT2654769T (pt) 2020-07-16
BR112013015001A2 (pt) 2017-12-19
EP2654769A2 (en) 2013-10-30
JP2014510699A (ja) 2014-05-01
WO2012080822A2 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
US9896512B2 (en) Antitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to NAP12B transporter
US10793633B2 (en) Therapeutic peptides
ES2770787T3 (es) Método y composición para tratar el cáncer, destruir las células cancerosas metastásicas y evitar la metástasis del cáncer usando anticuerpo para productos finales de glicación avanzada (AGE)
ES2994374T3 (en) Antibody molecule-drug conjugates and uses thereof
Landon et al. Is phage display technology on target for developing peptide-based cancer drugs?
US12528846B2 (en) BH4 stabilized peptides and uses thereof
US20090274625A1 (en) Compositions and Methods for The Treatment of Cancer
JP7376476B2 (ja) Ｂｃｌ９ペプチドおよびそのバリアント
US10632179B2 (en) Methods and compositions for treating cancer
CA3160636A1 (en) Methods and compositions for treating cancer
Fetse Discovery and Delivery of Peptide-Based Immune Checkpoint Inhibitors Targeting PD-L1 for Cancer Immunotherapy
HK40105152A (zh) 对muc18特异性的抗体
CN118922715A (zh) 作为治疗哺乳动物中衰老细胞的预后或诊断标记物的p53磷酸化
HK1199835B (en) Therapeutic peptides

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2011, OBSERVADAS AS CONDICOES LEGAIS.